Communiqués Shionogi & Co., Ltd.

Actions

4507

JP3347200002

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
7 040 ^JPY	+0,92 %		+1,72 %	+3,56 %

14/05	L'action japonaise Nikkei se maintient dans une fourchette étroite, dans l'attente des résultats des entreprises locales et des chiffres de l'inflation américaine.	RE
13/05	Le Japonais Shionogi déclare que le traitement COVID n'a pas atteint le critère d'évaluation lors d'un essai de phase avancée	RE

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shionogi & Co., Ltd. - Launch of the Gram-negative Bacterial Infection Treatment FETROJA 1g, in Taiwan	29/05	AQ
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	13/05	AQ
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	09/05	AQ
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04	AQ
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04	AQ
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04	AQ
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04	AQ
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03	AQ
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06/03	AQ
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	06/03	AQ
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	05/03	AQ
Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition	04/03	AQ
Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University	04/03	AQ
Shionogi Announces appointment of Auditors, Corporate officers, Corporate Reorganization and Personnel Reassignment	29/02	AQ
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02	AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02	AQ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02	AQ
Shionogi - Announcement of the Strategic Business Partnership Agreement for Diagnosis Support AI Program in Dementia and Depression between FRONTEO and Shionogi	15/02	AQ
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open	14/02	AQ
Shionogi & Co., Ltd. - Recognized with the Double a List for Leadership in Corporate Transparency and Performance on Climate Change and Water Security by CDP for the second consecutive year	08/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Shionogi & Co., Ltd.

Actions

4507

JP3347200002

Communiqués

Filtres